BIOTECH CATALYST AI SCANNER — July WK4

Programming note — the weekly AI Catalyst Scanner will run through the end of August 2026, then pause.

The economics of the weekly format have moved against it: the API and data costs behind each issue have risen steadily, and the honest reason we're not converting this into a paid product is that the underlying data quality and accuracy still aren't where they'd need to be to charge for it. The scanner does real work, but cash and runway figures, catalyst dates, and scoring all still require independent verification — and we won't put a subscription price on something we'd caveat that heavily. So the weekly cadence ends after the August issues. Occasional deep dives and one-off tips will continue on an irregular schedule, where the extra time per piece lets us fact-check properly rather than run the whole screen every seven days. Thank you for reading along — the next several weeks will be business as usual.

This week's slate is unusual for how tightly it clusters in time and how narrowly it clusters in score. Nearly every featured name points at a late-August window — a wall of estimated mid-to-late-2026 data readouts and a handful of hard PDUFAs (Capricor July 29, Moderna August 5, Ultragenyx August 23) landing inside the next six weeks. There's no runaway standout this issue: the featured BSI scores compress into a 5.4–6.5 band, with nothing in the 7-plus "fortress" tier that Celcuity or Seres occupied earlier this summer.

The tilt worth flagging is data-type. A lot of what cleared the window is estimated-timing topline, interim, or first-in-human data rather than binary regulatory dates — ArriVent, Silence, Neurogene, Corbus, Sutro all carry "Aug 2026 (Est.)" readouts, which means the calendar could slip. And two of the entangled watchlist names — Ionis and AstraZeneca — are here on a trial that already missed: the eplontersen (Wainua) CARDIO-TTRansform study in ATTR cardiomyopathy failed its primary endpoint on July 9, with full data reserved for ESC in August. Read the lower half of this issue with the same caution the scores imply.

What We're Tracking:

Trading Below Cash: ACET
Cash Pressure: OTLK, TRDA, NTHI, CHRS
Initial / First-Human Data: AVBP, SLN, NTHI, LGVN, SION, CRBP
Multi-Catalyst: NTHI, SION, AZN

FEATURED

#1. AVBP — ArriVent BioPharma Inc.

THE CATALYST
Event: Furmonertinib (FURVENT) — Phase 3 Topline Data in 1L EGFR exon 20 insertion NSCLC
Date: Aug 2026 (Est.)
FDA Status: BTD
BSI: 7.48/10

ArriVent's Phase 3 topline slipped from early to mid-2026 for a benign reason — slower event accrual, not enrollment or operational trouble — which preserves the trial's original statistical powering rather than signaling weakness. The company in-licenses differentiated oncology assets, mostly from Chinese developers, with furmonertinib partnered with Allist Pharmaceuticals; a 2025 deal for a preclinical GI antibody-drug conjugate from Lepu Biopharma widened the pipeline around a focused EGFR-mutant NSCLC franchise.

📈 The Setup: In first-line non-small-cell lung cancer driven by EGFR exon 20 insertion mutations (a gene alteration that switches on tumor growth), targeted options are thin — amivantamab (Rybrevant) plus chemotherapy sets a modest bar while carrying infusion and toxicity baggage. Furmonertinib is an oral, brain-penetrant, mutant-selective EGFR tyrosine kinase inhibitor (a pill that blocks the mutated growth signal), and its Phase 3 pits it head-to-head against chemotherapy — a cleaner lane than the combination backbones rivals need. The Phase 1b FAVOUR trial showed a 78.6% confirmed response rate in treatment-naïve patients with a 15.2-month median duration of response. With RSI at 17.6 and the stock discounted as a me-too, this is a contrarian setup priced for failure ahead of a topline that tests whether that oral, CNS-active profile translates.

✅ The Edge: The only oral monotherapy in Phase 3 against chemotherapy in this niche, with Breakthrough Therapy Designation and brain penetrance that intravenous amivantamab can't match — a convenience and CNS argument in a population with few targeted choices.
⚠️ The Risk: The FDA has historically scrutinized progression-free survival in open-label exon 20 trials and may demand overall-survival trends or CNS-subgroup consistency. A modest hazard ratio against amivantamab-chemo, or the open-label design itself, could blunt both approval odds and uptake.

#2. SLN — Silence Therapeutics plc

THE CATALYST
Event: Divesiran (SANRECO) — Phase 2 Topline Data in polycythemia vera
Date: Aug 2026 (Est.)
FDA Status: FTD, ODD
BSI: 7.41/10

AstraZeneca declined further development of partnered asset SLN312 after Phase 1 in March 2026, returning global rights to Silence, and its Lp(a) drug zerlasiran is now positioned for external partnering — both moves sharpen the focus onto divesiran's near-term readout. Silence is a UK-domiciled (plc) RNA-therapeutics developer whose remaining platform collaboration with AstraZeneca continues on separate targets.

📈 The Setup: Polycythemia vera — an overproduction of red blood cells — is managed today with repeated therapeutic phlebotomy plus cytoreductive agents like hydroxyurea, ruxolitinib (Jakafi), or ropeginterferon (Besremi). Divesiran takes a different angle: it's an siRNA (a short interfering RNA that silences a target gene) that shuts down TMPRSS6 in the liver to raise hepcidin, restricting the iron supply erythropoiesis needs. In the Phase 1/2 SANRECO study, hematocrit fell to ≤45% and therapeutic phlebotomies were near-eliminated across dosing cohorts, and June 2026 EHA follow-up showed those effects held regardless of baseline. No siRNA or hepcidin-modulating rival exists in the indication. With momentum running hot (+51%), the August topline is the confirmation the setup is pricing in.

✅ The Edge: Divesiran stands alone in Phase 2 with an iron-restriction mechanism no competitor is pursuing in PV, backed by Fast Track and Orphan Drug designations and a convenient infrequent subcutaneous schedule versus daily oral cytoreductives.
⚠️ The Risk: The evidence rests on a small Phase 2 and surrogate endpoints — phlebotomy rate and hematocrit — that may not translate against entrenched JAK-inhibitor and interferon use, and any durability wobble or iron-parameter safety signal would undercut the thesis.

#3. PYXS — Pyxis Oncology Inc.

THE CATALYST
Event: Micvotabart pelidotin (MICVO) — Phase 1 Interim Data in solid tumors (HNSCC)
Date: Aug 2026 (Est.)
FDA Status: FTD, ODD
BSI: 7.32/10

A June 2026 private placement — $50 million, up to $114 million with warrants, led by BVF Partners — explicitly funds the updated data into Fall 2026 and pushes runway into Q2 2027, taking near-term cash pressure off the table (a new chief business officer arrived the same month). Pyxis is a Boston antibody-drug-conjugate developer whose lead program, MICVO, is in-licensed from Pfizer.

📈 The Setup: In recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), pembrolizumab (Keytruda) monotherapy sets a low bar — response rates in the mid-teens in later lines. MICVO is an antibody-drug conjugate (an antibody wired to a cell-killing payload, here a microtubule inhibitor) that delivers its toxin inside tumor cells. Early Phase 1 numbers were striking: 46% confirmed response and 92% disease control as monotherapy, rising to 71% response and 100% disease control in combination with Keytruda. Tisotumab vedotin — approved in cervical cancer — is the nearest ADC exploring this space. The whole thesis rides on whether the Fall 2026 update shows those signals are durable rather than small-sample noise; this is an interim look, not a pivotal readout.

✅ The Edge: A dual mechanism that pairs targeted payload delivery with PD-1 blockade, producing a 71% combination response rate well above Keytruda-monotherapy benchmarks, plus Fast Track and Orphan designations behind it.
⚠️ The Risk: The efficacy rests on tiny, single-arm, non-randomized numbers; the FDA has historically required randomized confirmation of response durability in HNSCC before pivotal advancement, and durability shortfalls versus approved PD-1 agents or tisotumab vedotin would deflate the readout.

#4. CAPR — Capricor Therapeutics Inc.

THE CATALYST
Event: Deramiocel (CAP-1002) — PDUFA Regulatory Decision in Duchenne muscular dystrophy
Date: Jul 29, 2026 (Ad Com)
FDA Status: ODD
BSI: 7.31/10

HOPE-3 hit the exact endpoints the FDA cited as missing in its July 2025 complete response letter, converting that rejection into a July 29 advisory-committee meeting and a Class 2 resubmission PDUFA of August 22. Capricor is a San Diego cell- and exosome-therapy developer; deramiocel is commercialized under an exclusive U.S. and Japan agreement with Nippon Shinyaku, and a new San Diego headquarters lease is contingent on approval.

📈 The Setup: Duchenne care is crowded — Sarepta's exon-skippers (Exondys 51, Vyondys 53, Amondys 45) and its Elevidys gene therapy address skeletal muscle — but the cardiomyopathy that ultimately kills patients stays largely untreated. Deramiocel is an allogeneic cardiosphere-derived cell therapy (donor-derived cardiac progenitor cells that dampen inflammation and fibrosis), and it's mutation-agnostic. In the Phase 3 HOPE-3 trial it reached statistical significance on the primary upper-limb endpoint (PUL v2.0) and the key cardiac secondary (left-ventricular ejection fraction), while the five-year HOPE-2 extension showed sustained function across more than 800 infusions. With the stock oversold (RSI 17) and momentum deeply negative, the market looks anchored to the resolved CRL rather than the data that lifted it — the July 29 panel is the swing.

✅ The Edge: Potentially the first therapy specifically for DMD cardiomyopathy, mutation-agnostic and backed by multi-year dual-tissue durability data no competitor has matched — addressing the cardiac failure Elevidys and exon-skippers don't directly treat.
⚠️ The Risk: The prior CRL flagged insufficient substantial evidence of effectiveness, and cell-therapy precedent at advisory committees for rare neuromuscular disease is thin — the panel could still land on a second complete response or a narrow cardiomyopathy-only label.

#5. MRNA — Moderna Inc.

THE CATALYST
Event: mRNA-1010 (P304) — PDUFA Regulatory Decision in seasonal influenza, adults 50+
Date: Aug 05, 2026
BSI: 7.19/10

Moderna's flu BLA got a refusal-to-file letter in February 2026, then cleared its advisory committee 9-0 on benefit-risk four months later — an unusually fast turnaround for a first-in-class filing. The company's core is mRNA vaccines and therapeutics, anchored by a Merck partnership on the personalized cancer vaccine mRNA-4157; a ~$950 million litigation settlement due in Q3 2026 is part of the backdrop as it diversifies beyond COVID.

📈 The Setup: The seasonal flu market is entrenched — standard-dose inactivated shots (Fluarix from GSK, Fluzone from Sanofi) plus high-dose and adjuvanted options for older adults. mRNA-1010 encodes hemagglutinin antigens (the surface proteins the immune system learns to recognize) for influenza A and B, and it's the only mRNA flu candidate to reach a BLA decision. The pivotal P304 trial (~41,000 adults 50+) delivered 26.6% relative efficacy versus standard-dose comparators, with higher antibody titers and consistent strain-level results. Coming off a unanimous panel vote into an August 5 decision, the stock already reflects meaningful approval odds — the open questions are absolute benefit magnitude and manufacturing scale, not whether the data cleared the bar.

✅ The Edge: The sole mRNA influenza vaccine at the approval stage, carrying a 9-0 advisory-committee vote and superiority over standard-dose shots, with Moderna's existing mRNA manufacturing base offering scale rivals' nascent efforts lack.
⚠️ The Risk: The prior refusal-to-file plus modest absolute efficacy in a well-vaccinated population leaves room for a CRL or label limits, and incumbents with lower reactogenicity and locked-in formulary spots can squeeze pricing even after approval.

#6. NTHI — NeOnc Technologies Holdings Inc.

THE CATALYST
Event: NEO100 — Phase 2a Topline Data in recurrent IDH1-mutant astrocytoma
Date: Aug 2026 (Est.)
Additional catalysts: 1 more within 90 days
BSI: 7.14/10

Insider conviction is unusually visible here — the CEO and chairman have bought more than $500,000 of stock — alongside a January 2026 $10 million PIPE led by Cinctive Capital and a June UAE IND clearance, all ahead of the readout. But the balance sheet is the counterweight: verified runway reaches only into September 2026. NeOnc is a Calabasas developer focused on intranasal drug delivery for central-nervous-system cancers.

📈 The Setup: For recurrent WHO Grade 3/4 IDH1-mutant astrocytoma, no targeted therapy is approved — patients get bevacizumab or lomustine, and vorasidenib is cleared only for Grade 2 disease. NEO100 is intranasal perillyl alcohol (a monoterpene with alkylating and pro-apoptotic activity) delivered nose-to-brain, bypassing the blood-brain barrier that blocks systemic agents. In the expanded Phase 1/2a cohort (n=25) it produced a 24% radiographic remission rate versus the sub-8% typically seen with salvage therapy, with 44% six-month progression-free survival. The imminent topline is a direct test of whether that signal holds under controlled analysis. This is maximum binary pressure — micro-cap, oversold, low float, and a financing clock running right up against the data.

✅ The Edge: A 24% remission rate that roughly triples the historical salvage benchmark, delivered through a nose-to-brain route no systemic IDH inhibitor or standard regimen replicates in contrast-enhancing recurrent disease.
⚠️ The Risk: A single small, open-label cohort read on radiographic endpoints is exactly what the FDA has historically declined for glioma approvals absent randomized PFS or OS — and with cash only into September, financing has to arrive essentially on top of the readout.

#7. LGVN — Longeveron Inc.

THE CATALYST
Event: Laromestrocel (ELPIS II) — Phase 2b Topline Data in hypoplastic left heart syndrome
Date: Aug 2026 (Est.)
FDA Status: FTD, ODD
BSI: 6.93/10

The single most important fact heading in is a setback: a late-March 2026 FDA Type C meeting determined that right-ventricle ejection fraction is not an appropriate primary endpoint, and the trial is no longer described as pivotal — even as the independent data-monitoring committee endorsed continuation in May. Longeveron is a Miami developer of allogeneic cell therapies for rare pediatric and aging-related conditions, with a separate Alzheimer's program holding RMAT and Fast Track status.

📈 The Setup: Hypoplastic left heart syndrome is treated with staged surgical palliation (Norwood, Glenn, Fontan) and, in some cases, transplant — there's no approved cell or disease-modifying therapy. Laromestrocel is an allogeneic mesenchymal stem-cell therapy (young-donor cells with pro-vascular, anti-inflammatory, and tissue-repair effects) injected into the heart muscle as an adjunct to Stage II surgery. The Phase 1 ELPIS I study (n=10) showed 100% transplant-free survival to age 5 against grim historical rates, and ELPIS II (n=40) reads out this August. But the endpoint downgrade is the story: what could have been a pivotal result is now a data point that needs a revised, post-hoc endpoint to gain any regulatory footing. At a $19M cap this is deep value — with a real regulatory hole in the middle of it.

✅ The Edge: The only late-stage regenerative program in HLHS, carrying Fast Track, Orphan, and Rare Pediatric Disease designations that keep a priority-review-voucher path alive if the topline lands convincingly on a revised composite endpoint.
⚠️ The Risk: The FDA rejected the primary endpoint and won't pre-agree a replacement, so even positive topline data could force a larger confirmatory trial — and a 40-patient, single-indication study leaves little room for variability.

#8. NGNE — Neurogene Inc.

THE CATALYST
Event: NGN-401 (Embolden) — Phase 1/2 Interim Data in Rett syndrome
Date: Aug 2026 (Est.)
FDA Status: BTD, RMAT
BSI: 6.92/10

Dosing is complete in the 25-patient Embolden registrational trial (reported June 8, 2026), which sets up mid-2026 Phase 1/2 updates ahead of a topline registrational readout in the second half of 2027. Neurogene is a New York gene-therapy developer with no major partnerships disclosed; the Rett program is its lead and its only near-term data generator, funded by a balance sheet that reaches into 2029.

📈 The Setup: Rett syndrome is treated symptomatically with trofinetide (Daybue, from Acadia); there's no approved disease-modifying option. NGN-401 is an AAV9-based gene therapy (a viral vector delivering a working copy of a gene) carrying a functional MECP2 gene — the gene mutated in Rett — administered directly into the cisterna magna. Prior Phase 1/2 data in small low- and high-dose cohorts showed dose-dependent improvements on the Rett Clinical Severity Scale with manageable safety. Taysha's TSHA-102, also an AAV9-MECP2 approach, is the nearest rival, still in Phase 1/2. With cash into 2029, this is a Fortress that can pick its moments — but the August event is an interim update, not the registrational answer, and should be read as color rather than proof.

✅ The Edge: Registrational-stage with enrollment complete, ahead of most gene-therapy rivals in Rett, and carrying both Breakthrough and RMAT designations plus a runway into 2029 that removes financing pressure through the pivotal readout.
⚠️ The Risk: MECP2 gene therapy carries an overexpression-toxicity risk seen in prior programs, and an interim look invites scrutiny on durability and safety monitoring well before the 2H 2027 topline can settle the efficacy question.

#9. RARE — Ultragenyx Pharmaceutical Inc.

THE CATALYST
Event: DTX401 (pariglasgene brecaparvovec) — PDUFA Regulatory Decision in glycogen storage disease type Ia
Date: Aug 23, 2026
BSI: 6.69/10

Management has framed 2026 around two potential approvals and expense discipline aimed at profitability in 2027 — DTX401 is one of the two, carrying a Priority Review and an August 23 PDUFA. Ultragenyx is a Novato, California rare-disease developer that already markets Crysvita and Dojolvi while advancing multiple late-stage programs.

📈 The Setup: Glycogen storage disease type Ia has no disease-modifying therapy; standard care is uncooked cornstarch dosed around the clock to maintain blood sugar. DTX401 is an AAV8 gene therapy (a viral vector delivering a functional gene to liver cells) carrying G6PC — the enzyme patients lack — to restore endogenous glucose production. In the randomized Phase 3 GlucoGene trial (n=44), it cut daily cornstarch intake 41.3% at week 48 versus 10.3% on placebo (p<0.0001), with 61% mean reductions by week 96 and nighttime doses eliminated in two-thirds of patients. Beam Therapeutics' base-editing BEAM-301 sits far behind in Phase 1/2. This is a binary regulatory event on the only Phase 3 asset in the indication.

✅ The Edge: The sole program with Phase 3 data and a completed BLA under Priority Review in GSDIa — the first candidate to correct the underlying enzyme defect rather than manage it, with no competitor at comparable stage.
⚠️ The Risk: AAV liver-directed therapies have drawn FDA requests for longer-term durability or additional CMC data even after Priority Review, and a single small Phase 3 with crossover design leaves limited room for endpoint-interpretation disputes.

#10. CHRS — Coherus Oncology Inc.

THE CATALYST
Event: Casdozokitug/toripalimab/bevacizumab — Phase 2 Initial Data in hepatocellular carcinoma
Date: Aug 2026 (Est.)
BSI: 6.39/10

After divesting its biosimilar operations in 2025 and rebranding from Coherus BioSciences, the company is now a pure immuno-oncology play with debt cut more than 90% from prior peaks. Coherus is based in Redwood City, California, and holds rights to the PD-1 inhibitor toripalimab through a partnership with Junshi Biosciences; a February 2026 offering and Q1 sales added roughly $54 million net.

📈 The Setup: First-line hepatocellular carcinoma is owned by atezolizumab plus bevacizumab (the IMbrave150 regimen). Casdozokitug is an anti-IL-27 monoclonal antibody (it blocks an immunosuppressive cytokine that damps down T-cell activity in the tumor microenvironment), layered on a PD-1/VEGF backbone to deepen responses. Earlier Phase 2 data noted in January 2025 showed a 17.2% complete-response rate — high for the setting — and improved depth of response. The mid-2026 readout tests whether that holds in the atezolizumab/bevacizumab combination or reflects small-sample variability. Other PD-1/VEGF combinations in development are the competitive frame; casdozokitug's differentiation rests entirely on whether IL-27 blockade adds something measurable.

✅ The Edge: IL-27 inhibition is a genuinely differentiated mechanism on top of standard PD-1/VEGF therapy, and the prior 17.2% complete-response rate sits above what the atezolizumab/bevacizumab backbone delivers alone.
⚠️ The Risk: First-line HCC is entrenched, and single-arm response rates alone have faced endpoint rejections in this setting — without a clear additive survival or depth-of-response signal, the readout confirms limited differentiation rather than a path forward.

WATCHLIST

#11. OTLK — Outlook Therapeutics Inc. [Ophthalmology]

Price: $1.38 | Cap: $258.1M | Cash: $8.0M | RSI: 37.2 | Momentum: -12.7%
LYTENAVA (bevacizumab-vikg) — PDUFA Regulatory Decision in wet AMD (Jul 29, 2026)
BTD
BSI: 6.93/10

The Intel: Outlook's third swing at U.S. approval for LYTENAVA, an on-label ophthalmic anti-VEGF (it blocks the vessel-growth factor behind wet age-related macular degeneration) positioned against off-label compounded Avastin and branded Eylea, Lucentis, and Vabysmo. The July 29 Class 1 resubmission follows multiple prior rejections; with roughly $8M cash and a thin data package, financing risk rides right alongside the binary. Breakthrough status helps — the balance sheet doesn't.

#12. CABA — Cabaletta Bio Inc. [Immunology]

Price: $2.75 | Cap: $448.4M | Cash: $213.7M | RSI: 38.2 | Momentum: -3.2%
Resecabtagene autoleucel (RESET-MG) — Phase 1/2 Interim Data in generalized myasthenia gravis (Aug 2026 (Est.))
BSI: 6.74/10

The Intel: Cabaletta's rese-cel is a CD19-targeted CAR-T therapy (engineered T cells that eliminate antibody-producing B cells) aiming for a one-time immune reset in generalized myasthenia gravis — a contrast to chronic FcRn blockers like argenx's Vyvgart. A mid-2026 Phase 1/2 update follows April AAN data, and $214M in cash removes near-term financing pressure. But this is an interim look, not a controlled efficacy readout, and the fully human CAR construct still has to prove its durability edge.

#13. TRDA — Entrada Therapeutics Inc. [Neuromuscular]

Price: $6.34 | Cap: $246.1M | Cash: $24.6M | RSI: 29.3 | Momentum: -10.6%
ENTR-601-45 (ELEVATE-45-201) — Phase 1/2 Initial Data in Duchenne muscular dystrophy (Aug 2026 (Est.))
BSI: 6.59/10

The Intel: Entrada's ENTR-601-45 uses endosomal-escape-vehicle technology to carry an exon-45-skipping oligonucleotide (a synthetic strand that patches the dystrophin reading frame) into muscle, pitched as far better intracellular uptake than Sarepta's approved PMOs. The data-monitoring committee just cleared a Cohort 2 escalation to 10 mg/kg. But the runway is tight (Cash Crunch flag) and this is an early safety and exon-skipping look — not the validated functional data the FDA has required in Duchenne.

#14. MNPR — Monopar Therapeutics Inc. [Rare Disease]

Price: $105.90 | Cap: $709.4M | Cash: $48.2M | RSI: 62.7 | Momentum: +57.0%
ALXN1840 (WTX101 / FoCus) — NDA Filing in Wilson disease (Aug 2026 (Est.))
BSI: 6.48/10

The Intel: Monopar licensed ALXN1840 (a copper-binding agent that clears toxic free copper into stable complexes for excretion) from Alexion/AstraZeneca and is steering it toward a Wilson disease NDA, with a June 2026 Rare Pediatric Disease designation. The pitch is avoiding the early neurological worsening common with chelators like trientine. A 6.7M-share micro-float plus +57% momentum leaves the stock technically stretched into an estimated-timing filing rather than a hard date.

#15. SION — Sionna Therapeutics Inc. [Pulmonology]

Price: $45.69 | Cap: $2.06B | Cash: $189.0M | RSI: 55.7 | Momentum: +22.5%
SION-451 + SION-109 — Phase 1 Topline Data in cystic fibrosis (Aug 2026 (Est.))
Additional catalysts: 2 more within 90 days
BSI: 6.46/10

The Intel: Sionna is testing a novel CFTR-modulator pair — SION-451 (stabilizes the misfolded chloride channel that causes cystic fibrosis) plus SION-109 (boosts the channel's gating) — against Vertex's entrenched Trikafta franchise. Three readouts cluster in mid-2026, including the Phase 2a SION-719 proof-of-concept. First-in-human safety data carry real uncertainty this early, but a $2B market cap already prices in meaningful platform optionality ahead of proof.

#16. ACET — Adicet Bio Inc. [Immunology]

Price: $7.89 | Cap: $73.8M | Cash: $110.8M | RSI: 40.7 | Momentum: -2.6%
Prula-cel (formerly ADI-001) — Phase 2 Interim Data in systemic lupus erythematosus (Aug 2026 (Est.))
FTD
BSI: 6.37/10

The Intel: Adicet's prula-cel is an off-the-shelf allogeneic gamma-delta CAR-T (donor immune cells that target CD20 on B cells) attempting an immune reset in lupus without patient-specific manufacturing — a logistics edge over autologous CAR-Ts from Kyverna and Cabaletta. It trades below net cash (negative enterprise value) with Fast Track status, but a mid-2026 interim in a small program leaves the core efficacy question wide open.

#17. AZN — AstraZeneca plc [Rare Disease]

Price: $164.52 | Cap: $262.6B | Cash: $9.12B | RSI: 29.5 | Momentum: -6.0%
ALXN1840 (FoCus) — NDA Filing in Wilson disease (Aug 2026 (Est.))
Additional catalysts: 1 more within 90 days
BSI: 6.31/10

The Intel: AstraZeneca surfaces here on two rare-disease filings, but read the fine print. The ALXN1840 Wilson asset is now Monopar's to develop, and the more material event — the eplontersen (Wainua) CARDIO-TTRansform trial in ATTR cardiomyopathy — missed its primary composite endpoint on July 9, with full data reserved for ESC in August. For a mega-cap, neither moves the needle; the ATTR miss is the real signal, not the Wilson line.

#18. IONS — Ionis Pharmaceuticals Inc. [Cardiology]

Price: $52.95 | Cap: $8.75B | Cash: $932.5M | RSI: 17.0 | Momentum: -28.6%
Wainua (eplontersen / CARDIO-TTRansform) — Phase 3 Conference Presentation in ATTR-CM (Aug 31, 2026)
FTD
BSI: 6.30/10

The Intel: Ionis's eplontersen (Wainua) — an antisense oligonucleotide (it blocks production of the TTR protein that forms amyloid) partnered with AstraZeneca — missed the primary composite endpoint in the CARDIO-TTRansform cardiomyopathy trial reported July 9, with full data at ESC in August. The mechanism validated in polyneuropathy didn't carry to this cardiac endpoint, where BridgeBio's Attruby and Pfizer's tafamidis already compete. This is a disappointment on the calendar, not a catalyst.

#19. STRO — Sutro Biopharma Inc. [Oncology]

Price: $22.59 | Cap: $374.3M | Cash: $260.0M | RSI: 13.0 | Momentum: -23.8%
STRO-004 — Phase 1 Initial Data in solid tumors (Aug 2026 (Est.))
BSI: 6.23/10

The Intel: Sutro's STRO-004 is an antibody-drug conjugate (an antibody linked to a tumor-killing payload) built on the company's cell-free, site-specific conjugation platform, meant to yield more uniform and stable molecules than conventional ADCs from AbbVie or Pfizer. First Phase 1 data arrive mid-2026. With no prior clinical evidence behind the asset and the stock deeply oversold (RSI 13), this is a pure first-look gamble on the platform.

#20. CRBP — Corbus Pharmaceuticals Holdings Inc. [Metabolic]

Price: $8.89 | Cap: $164.7M | Cash: $106.4M | RSI: 48.5 | Momentum: +7.6%
CRB-913 (CANYON-1) — Phase 1b Topline Data in obesity (Aug 2026 (Est.))
BSI: 6.23/10

The Intel: Corbus's CRB-913 is a peripherally restricted CB1 inverse agonist (it blocks the cannabinoid-1 receptor outside the brain) for obesity, designed to avoid the psychiatric side effects that sank first-generation CB1 drugs like rimonabant. Early Phase 1a showed 2.9% placebo-adjusted weight loss at day 14. The Phase 1b topline tests durability against GLP-1 incumbents Wegovy and Zepbound — a steep bar for a small-molecule newcomer, and the scoring here leaned on fallback estimates.

Disclaimer

The information provided is for informational purposes only and should not be construed as financial, investment, legal, or professional advice.

Key Risks:

Clinical trials: Most drug candidates fail in development
Regulatory: FDA decisions remain unpredictable
Financing: Companies may dilute at any time
Volatility: Small-cap biotech stocks experience extreme price swings

Past performance does not guarantee future results.

Scanner Version: 3.3 | Generated: 2026-07-21T10:25:12